Ekso Bionics Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Tables)

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2018

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The Company’s fair value hierarchies for its financial assets and liabilities which require fair value measurement are as follows:



	Total		Level 1		Level 2		Level 3
September 30, 2018
Liabilities
Warrant liabilities	$	1,810	$	—	$	—	$	1,810
Contingent consideration liability	$	47	$	—	$	—	$	47
Contingent success fee liability	$	33	$	—	$	—	$	33

December 31, 2017
Liabilities
Warrant liability	$	1,648	$	—	$	—	$	1,648
Contingent consideration liability	$	42	$	—	$	—	$	42
Contingent success fee liability	$	39	$	—	$	—	$	39

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities for the period ended September 30, 2018, which were measured at fair value on a recurring basis:



	Warrant Liability		Contingent Consideration Liability			Contingent Success Fee Liability
Balance at December 31, 2017	$	1,648	$	42		$	39
Loss on revaluation of warrants issued in conjunction with 2015 financing	162		—			—
Gain on revaluation of liability	—		(5		)	(6		)
Reclassification from accrued liabilities	—		10			—
Balance at September 30, 2018	$	1,810	$	47		$	33